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Abstract
A breakdown in intestinal homeostasis results in inflammatory bowel diseases including coeliac
disease and allergy. Galectins, evolutionarily conserved β-galactoside-binding proteins, can
modulate immune-epithelial cell interactions by influencing immune cell fate and cytokine
secretion. In this study we investigated the ‘glycosylation signature’ as well as the regulated
expression of galectin-1 and -3 in human duodenal samples of allergic and non-allergic children.
Whereas galectin-1 was predominantly localized in the epithelial compartment (epithelial cells and
intraepithelial lymphocytes) and the underlying lamina propria (T cells, macrophages and plasma
cells), galectin-3 was mainly expressed by crypt epithelial cells and macrophages in the lamina
propria. Remarkably, expression of these galectins was not significantly altered in allergic versus
non-allergic patients. Investigation of the glycophenotype of the duodenal inflammatory
microenvironment revealed substantial α2–6-linked sialic acid bound to galactose in lamina
propria plasma cells, macrophages and intraepithelial lymphocytes and significant levels of asialo
core 1 O-glycans in CD68+ macrophages and enterocytes. Galectin-1 preferentially bound to
neutrophils, plasma cells and enterocytes, while galectin-3 binding sites were mainly distributed
on macrophages and intraepithelial lymphocytes. Notably, galectin-3, but not galectin-1 binding,
was substantially increased in intraepithelial gut lymphocytes of allergic patients compared to
non-allergic subjects, suggesting a potential role of galectin-3-glycan interactions in shaping
epithelial-immune cell connections during allergic inflammatory processes.
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Food allergies are becoming increasingly common worldwide. They consist of a spectrum of
disorders that result from adverse immune responses to dietary antigens (1).
Hypersensitivity to cow milk allergy is one of the most common food allergies in childhood
and constitutes a pathological condition in which oral tolerance against luminal cow’s milk
proteins is abrogated (1). Although the precise pathogenic mechanisms are unknown,
immunological responses to food may be IgE- or non-IgE- mediated. It seems possible that
during the chronic phase of an originally IgE-initiated allergic inflammation, the pathogenic
immune reaction responsible for clinical symptoms is dominated by allergen-specific T
lymphocytes. In this context, it has become increasingly evident that allergen-specific Th2
cells play a central role in the genesis and maintenance of the allergic inflammatory
reactions in both human subjects and mouse models (2–3). On the other hand, cell mediated
immunity has been implicated in IgE-independent gastrointestinal food hypersensitivity.
Activation of cytotoxic T lymphocytes has been described as the main pathogenic
mechanism in cow’s milk protein sensitive enteropathy (CMSE) (4).
Glycan structures, which decorate the surfaces of all mammalian cells, can substantially
change under different physiological and pathological conditions (5). In fact, glycosylation
of cell surface proteins can control critical immunological processes, including T-cell
activation, migration and apoptosis (6–7). Therefore, the physiology and pathology of a cell
is determined to a great extent by the complex information encoded by its cell surface
glycosylation pattern, which is decoded by various glycan-binding proteins, including C-
type lectins, siglecs and galectins (5, 8–9).
Galectins, a family of highly conserved carbohydrate-binding proteins, are characterized by
their ability to recognize multiple N-acetyllactosamine residues, which can be displayed on
both N- and O-glycans on cell surface glycoconjugates (8). Galectins have emerged as novel
regulators of immune cell homeostasis. Results from our laboratory demonstrated that
galectin-1 (Gal-1) contributes to immune cell tolerance by selectively eliminating Th1 and
Th17 pathogenic cells, thus promoting a shift toward a Th2-dominant cytokine profile (6,
10) or by favoring the expansion of regulatory T cells (11–12). On the other hand, Gal-3
induces activation of various inflammatory cell types (13), modulates T-cell apoptosis (13–
14) and induces a pro-inflammatory response (13, 15). However, Gal-3 can also have anti-
inflammatory activity under certain circumstances (16).
Although the role of galectins in inflammatory and allergic processes has been extensively
described (13, 15–16), the relevance of these glycan-binding proteins within the intestinal
microenvironment is poorly understood. Considering that the duodenum is an intestinal
region critical during the development of allergic responses to food antigens, and that Th2
cells and IELs are deeply involved in their pathogenesis, we investigated the binding of
Gal-1, Gal-3 and plant lectins to human duodenum samples of allergic and non-allergic
patients, as well as the regulated expression of these glycan-binding proteins, in an attempt
to characterize the human intestinal ‘glycosylation signature’ under physiological and
pathological conditions, and to further delineate the potential role of galectin-glycan lattices
within the intestinal microenvironment.
MATERIALS AND METHODS
Human samples and patients
The study group consisted of 16 patients (8 females and 8 males; mean age 1.5; range 1
month to 5 years) diagnosed as cow milk allergic (n: 8; mean age, 1.8 years; range, 1.5 to
2.5 years) or non-allergic (n: 8; sex- and age-matched). All patients were assisted at the
Gastroenterology Unit in the Sor María Ludovica Children’s Hospital (La Plata, Argentina).
Upper intestinal endoscopy was performed under general anesthesia. Biopsy samples were
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taken for routine histology, immunohistochemistry, lectin-histochemistry and confocal
microscopic analysis.
Cow milk allergy (CMA) diagnosis was performed on the basis of clinical suspicion of
milk-related symptoms (prolonged diarrhea, atopic dermatitis or broncoespasm after the
ingestion of cow′s milk), elevated total serum IgE levels and the presence of cow milk
specific IgE antibodies. Parasitic infections and lactose intolerance were discarded. Serum
IgA levels were normal in all patients (0.15–1.59 g/l). IgG and IgA anti-gliadin and anti-
transglutaminase were found to be negative, and two of the allergic patients had anemia and
blood in stools. After CMA diagnosis was performed, a strict milk-free diet was indicated.
All patients had clinical remission and showed a significant increase in weight and height
after 6 months of allergen avoidance. An extensively hydrolyzed cow′s milk formula or a
probiotic were indicated as a dairy substitute during the elimination diet. Written parental
consent was obtained for all patients and the project was approved by the local Ethics
Committee.
Histopathology and immunohistochemical methods
Specimens were fixed in 5% neutral buffered formalin and embedded in paraffin. Samples
were cut and mounted onto charged glass slides and heated at 60°C for 30 min. Briefly,
xylene and ethanol were used to deparaffinize and endogenous peroxidase activity was
blocked with 3% H2O2/methanol. Antigen retrieval was performed in buffer citrate (pH 6)
and slides were microwaved. Afterwards, non-specific sites were blocked with 1% BSA in
PBS and incubated with the primary antibody: anti-CD3 monoclonal antibody (1:25,
DAKO, CLONE F7.2.38; Glostrup, Denmark), biotinylated anti-human IgE (human ε chain
specific) (1:500, Vector Labs, Burlingame, CA, USA), anti-CD45RO monoclonal antibody
(1:300, DAKO, Glostrup, Denmark), anti-ST6Gal1 polyclonal antibody (1:200) (Sigma),
anti-Gal-1 rabbit antibody (1:200) generated as described (17) and polyclonal anti-Gal-3
(1:300). The anti-Gal-3 antibody was raised in rabbits using the purified recombinant Gal-3
(see below), affinity-purified on Protein A-Sepharose, and its specificity was validated by
Western blot. This was followed by the appropriate secondary antibodies: anti-mouse IgG-
biotin, anti-rabbit IgG-biotin and strepavidin-HRP conjugate (DAKO, Glostrup, Denmark).
3,3’-diaminobenzidine tetrahydrochloride chromogen (DAKO, Glostrup, Denmark) was
used for up to 2 min at room temperature for immunostaining. A serum from a non-
immunized rabbit was used as primary antibody for specificity controls. Controls omitting
the primary antibody were also performed. Sections were subsequently counterstained with
10% hematoxylin and mounted with Eukit. Stained sections were evaluated by two
independent pathologists blinded to the clinical or endoscopic data.
For routine histology examination the length of duodenal crypt and villi was assessed using
an ocular micrometer. Giemsa staining was performed to quantify mast cells, while
eosinophils were counted on hematoxylin-eosin stained sections. Different types of
infiltrating cells were counted per 6 villi.
For lectin-histochemistry, biotinylated lectins were used as the primary binding reagents:
Sambucus nigra agglutinin (SNA) (25 μg/ml, Vector Labs, Burlingame, CA, USA), peanut
agglutinin (PNA) (25 μg/ml, Vector Labs, Edelberry; Burlingame, CA, USA), recombinant
Gal-1 (10 μg/ml) generated as described (17) and recombinant Gal-3 (10 μg/ml). The
recombinant Gal-3 was expressed in E. coli from a construct based in the pET 30 Ek/Lic
vector (Novagen, Madison, WI), and purified on a lactosyl-Sepharose column. Streptavidin-
HRP (DAKO, Glostrup, Denmark) was used as secondary reagent. Controls were performed
by omitting the biotinylated lectins. A Nikon Eclipse E400 microscopy was used to analyze
the slides.
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Tissue staining and analysis by confocal microscopy
Immunofluorescence and confocal microscopy were performed with deparaffinized sections.
After antigen retrieval, samples were incubated with the primary antibody: anti-CD3 (1:25;
DAKO, CLONE F7.2.38, Glostrup, Denmark), anti-CD68 as a macrophage marker (1:50;
DAKO Clone M7228, Glostrup, Denmark), anti-CD138 as a plasma cell marker (1:25;
DAKO, Clone MI 15, Glostrup, Denmark), or biotinylated lectins (PNA, SNA, Gal-1 and
Gal-3) (Vector Labs, Burlingame, CA, USA). Anti-mouse-Cy3 (1:300; Jackson
Immunoresearch Laboratorioies Inc., PA, USA) or streptavidin-FITC (1:200; Sigma-
Aldrich, St Louis, MO, USA) were used as secondary reagents. DAPI (Invitrogen, Oregon,
USA) was used for nucleus staining. An LSM 510 Carl Zeiss Laser Scanning microscope
and an LSM5v3.2 software were used. For negative control staining the primary antibodies
or the biotinylated lectins were replaced by phosphate-buffered saline.
Validation of lectin binding
Different sugars were used as competitive inhibitors to validate lectin binding to the
glycosylated receptors. SNA, PNA and galectin binding were inhibited with 100 mM
lactose, 200 mM galactose, and 100 mM lactose respectively.
Statistical analysis
The data collected were analyzed using the Student′s t test for unpaired data to estimate the
significance of the differences between groups.
RESULTS
Expression and cellular distribution of Gal-1 and Gal-3 in the gut of allergic and non-
allergic patients
To determine the expression of Gal-1 and Gal-3 in duodenal samples of allergic and non-
allergic patients, we first performed a routine histological examination. Histopathological
analysis revealed no significant differences between samples of non-allergic and allergic
patients (Fig. 1). No specific cellular infiltrates were observed in the gut of allergic patients,
and CD3+ cell, mast cell, eosinophil and IgE-positive cell counts were not statistically
different when both groups were compared. In addition, there was no villous atrophy, and
villous or crypt heights were normal in all samples (villi/crypt ratio of 2.1 ± 0.6).
Several sources of endogenous Gal-1 and Gal-3 were found (Fig. 2). Galectin-1 was
predominantly expressed in the epithelial compartment, mainly epithelial cells and
intraepithelial lymphocytes (IELs) and in the underlying lamina propria (T cells,
macrophages and plasma cells), whereas Gal-3 was mainly found in crypt epithelial cells
and macrophages in the lamina propria (Fig. 2). Remarkably, expression of these galectins
was not significantly altered in the gut of allergic patients (Fig. 2), suggesting that the
contribution of galectin-glycan interactions in the transition to allergy may not be regulated
at the level of galectin expression in the intestinal inflammatory microenvironment.
Lectin binding sites within the duodenal microenvironment in allergic and non-allergic
subjects
To determine whether the transition from ‘non-allergic’ to ‘allergic’ inflammatory human
gut is accompanied by changes in cell surface glycosylation that could directly affect
galectin binding and immunoregulation, we studied the binding of exogenous biotin-labeled
lectins to mucosal tissues. It has been demonstrated that incorporation of α2–6-linked sialic
acid to N-glycans may be more restrictive for the binding of Gal-1 but not Gal-3 to cell
surface glycoproteins (6, 18). As depicted in Fig. 3 biotinylated SNA, a plant lectin that
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recognizes the SAα2–6-galactose sequence on N-glycans (6), preferentially bound
macrophages of the lamina propria, although a clear membrane staining was also observed
in intraepithelial lymphocytes. Double-staining analysis was performed by confocal
microscopy to evaluate the binding of SNA to CD3+ T lymphocytes. As shown in Fig. 3b,
SNA bound strongly to lamina propria CD3+ T cells. However, not all CD3+ T cells were
positive for SNA. Remarkably, no significant differences were found between samples of
allergic and non-allergic patients in the number of CD3+ SNA+ cells (10 ± 1 SNA+CD3+
cell/villi). Importantly, SNA binding was completely inhibited in the presence of 100 mM
lactose, demonstrating that lectin binding was saccharide-dependent (Fig. 3c). In addition,
the presence of α2–6-linked sialic acid was confirmed by immunohistochemical analysis of
the expression of α2–6 sialyltransferase 1 (ST6Gal 1), an enzyme responsible for generating
these glycan structures (Fig 3e). Expression of this glycosyltransferase was found in plasma
cells, T cells and, to a lesser extent, in epithelial cells of duodenal mucosa. Notably, no
differences were found between allergic and non-allergic samples.
Next, we probed cell surface glycoreceptors for the presence of asialo-core-1-O-glycans
using the lectin peanut agglutinin (PNA), which binds to galactose-β1–3-N-
acetylgalactosamine core-1-O-glycans and thus indicates lack of terminal α2–3-linked sialic
acid on these glycans. Interestingly, PNA binding correlated well with galectin binding to
the surface of different cell types (6). We found high PNA binding to intestinal macrophages
and enterocytes (supranuclear granules) (Fig. 4a). Remarkably, the glycocalyx coat was
highly stained by biotinylated PNA, demonstrating the abundance of asialo-core 1-O-
glycans on this structure (Fig 4a). Using confocal microscopy we found that CD68+
macrophages were highly positive for PNA staining (Fig. 4b). In contrast, no PNA+CD3+
cells could be detected, suggesting that CD3+ T cells are highly sialylated in the intestinal
mucosa (Fig. 4c). Specific binding was demonstrated by confocal microscopy using 100
mM galactose (Fig. 4d)
To further demonstrate the availability of glycan ligands for galectin recognition and
immunoregulation, we next performed lectin-histochemical analysis using biotinylated
Gal-1 and Gal-3. Staining with biotinylated Gal-1 revealed the presence of Gal-1 binding
sites predominantly on plasma cells, neutrophils and enterocytes (Fig. 5). Galectin-1 binding
strongly co-localized with CD138 (Syndecan-1), a transmembrane heparan sulfate
proteoglycan highly expressed by plasma cells. Importantly, Gal-1 binding was inhibited by
addition of 100 mM lactose, clearly demonstrating that this glycan-binding protein binds to
plasma cells in a saccharide-specific manner. Remarkably, we found no significant
differences in the extent of Gal-1 binding between gut samples of allergic and non-allergic
patients (Fig. 5). Of note, biotinylated Gal-1 was recognized by T cells in spleen biopsies of
control subjects (data not shown), yet it did not bind to CD3+ T cells from intestinal
biopsies, suggesting that the presence of α2–6-linked sialic acid on intraepithelial
lymphocytes (Fig. 3 b, c) might restrict Gal-1 recognition of its specific glycan ligands and
limit its subsequent functional effects.
In contrast, biotinylated Gal-3 clearly bound to macrophages, intraepithelial and lamina
propria T cells (Fig. 6). Also, the glycocalyx contained glycosylated components capable of
recognizing Gal-3, as illustrated in Fig. 6a. Noteworthy, lectin-histochemistry and confocal
microscopic analyses demonstrated substantially higher binding of Gal-3 to the surface of
CD3+ intraepithelial T lymphocytes in biopsies of allergic patients compared to non-allergic
subjects. Importantly, the total number of IELs did not statistically differ between normal
and allergic patients: 8.25 ± 0.78 and 8.37 ± 0.24 IELs/villi (P= 0.9), respectively. However,
the ratio of Gal-3+ IELs/total IELs per villi was 0.13 ± 0.05 for normal subjects and 0.73 ±
0.14 for allergic patients, clearly demonstrating that the transition from non-allergic to
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allergic mucosal tissue results in selective up-regulation of galectin-3-specific glycans on the
surface of IELs.
DISCUSSION
Research during the past decade has shed light on the role of galectin-glycan interactions at
different stages of the inflammatory responses (5, 8, 13). In addition, regulated expression of
galectins, as well as modulation of their specific ligands, is a common feature of the
transition from normal to inflamed or neoplastic tissues (19–20). In this study we
characterized the pattern of Gal-1 and Gal-3 expression and their glycan-binding profiles in
mucosal duodenum of normal individuals and allergic patients with a clinical outcome
compatible with hypersensitivity to cow milk proteins, in an attempt to delineate the
function of galectin-glycan lattices within the intestinal inflammatory microenvironment.
Our results clearly demonstrate that, in the absence of evident histopathologic alterations, an
early manifestation of cow milk allergy is represented by an up-regulated expression of
galectin-3-binding sites on the surface of IELs.
It still remains controversial whether the gut mucosa is histologically altered as a result of
food allergy. Although no histological alteration was found by Augustin and colleagues (21)
in CMSE patients, the authors observed a higher density of TUNEL+ CD3+ IELs. This may
reflect a compensatory mechanism to eliminate IELs during impaired immune responses to
food allergens. In our study we found no villous atrophy in the duodenum of allergic
patients. However, the presence of CD3+ IELs expressing the repertoire of glycans critical
for Gal-3 binding might contribute to alterations of gut homeostasis and permeability. As
Gal-3 has important pro-inflammatory properties (13), it is possible that Gal-3-activated
IELs might drive inflammation and an uncontrolled response to food antigens. Interestingly,
in our study, samples of allergic patients showed no considerable increase in the number of
CD3+ IELs, or in the frequency of CD3+ cells infiltrating the lamina propria, although most
T cells were activated (CD3+CD45RO+ cells). Kokkonen and colleagues (22) found similar
results in CMA patients with no villous atrophy or cell infiltration. However, they found a
higher density of CD3+ γδ+ IEL. Taken together, these results suggest an increased number
of IELs might be a marker of young adult duodenum with CMSE.
Galectins and their specific glycan ligands are abundant within the gastrointestinal tract (23–
24). Brinck and colleagues studied inflammation- and neoplasia-associated alterations in
human large intestine and found critical differences in the lectin binding profile following
acute peritonitis and tumorigenesis in the goblet cell population (24). Previous studies
reported that Gal-1 and Gal-3 mRNA are weakly expressed in the lamina propria of the
small intestine (25). Conversely, we found that epithelial cells and IELs were a major source
of Gal-1. This striking observation suggests that this lectin might be involved in host-
pathogen/commensal interactions, in epithelial cell homeostasis, or in the modulation of
mucosal tolerance and inflammation. This assumption is supported by the ability of
recombinant Gal-1 to suppress inflammatory bowel disease in mice (26). On the other hand,
Gal-3, which is mainly produced in the crypt, may also be involved in epithelial cell
proliferation or in immune cell activation. Strikingly, we did not find differences in Gal-1 or
Gal-3 expression between tissues from non-allergic and allergic patients. As galectins are
regulated during pathological conditions (27–29), further studies are warranted to analyze
whether galectin expression is modified in response to allergic inflammation or following
immunotherapy in experimental models or clinical settings.
According to our results, Gal-1 may not be involved in lamina propria T cell (LPTC)
homeostasis although it clearly binds to peripheral T cells (6) or to Th1/Th17-skewed
inflammatory mucosal T cells (26). Thus, one might speculate that under steady-state
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conditions or Th2-driven allergic responses, mucosal T cells are decorated by α2–6-linked
sialic acid, thus restricting Gal-1 binding and its subsequent immunoregulatory effects (6).
However, Gal-3 may successfully regulate Th2-driven inflammation in the mucosa during
allergic inflammation, as has been previously demonstrated in mouse models (15–16).
Intriguingly, Gal-2, a proto-type galectin structurally related to Gal-1, might play a
compensatory role in mucosal homeostasis as it is widely expressed within the
gastrointestinal tract (27).
Regarding the ligand selectivity of galectins, it is apparent that neither Gal-1 nor Gal-3
would bind to glycans containing only one lactosamine (Galβ1,3(4)GlcNAc) with α2,6
sialyation on its non-reducing terminal galactose residues, as the 6-OH of the galactose
residue is critical for galectin binding. However, if a glycan contains more than two
lactosamine residues, one of which bearing α2,6 sialyation, a difference between Gal-1 and
Gal-3 glycan binding would then become evident. As Gal-1 preferentially recognizes
peripheral (non-reducing terminal) β-galactoside residues, the incorporation of sialic acid in
α2,6 linkage to the non-reducing terminal galactoside may significantly reduce binding of
this lectin. In contrast, as Gal-3 binds to internal β-galactoside residues, the impact of sialyl
modification with α2,6 linkage is relatively lower than for Gal-1. As most glycans found on
cell surface glycoproteins contain more than two lactosamine residues, some of which are
not sialylated in α2,6, the overall affinity of Gal-3 for α2,6 sialylated glycans looks higher
than Gal-1 (9, 18).
In our study, SNA, which recognizes α2–6-linked sialic acid, bound to membrane
glycoproteins in lamina propria macrophages, plasma cells and IELs at the same extent in
allergic and non-allergic patients. This was confirmed by immunohistochemistry using a
specific anti-ST6Gal1 antibody supporting the fact that Th2-polarized cells as well as other
immune cell types display abundant cell surface expression of α2–6-linked sialic acid (5–6).
On the other hand, PNA, that specifically recognizes asialo-core-1-O-glycans, labeled
macrophages, epithelial cells and mucin produced by goblet cells. In this regard, PNA is a
classical marker of immature thymocytes and activated T cells (6), but can also recognize
macrophage glycoproteins (30). Of note, no PNA binding to LPTC could be detected in our
study. Interestingly, we previously found that human and mouse CD4+ T cells, polarized
toward Th1 or Th17 phenotypes, displayed abundant PNA-reactive asialo-core-1-O-glycans.
On the contrary, Th2 cells showed limited PNA binding (6). In this study, we found high
PNA binding to intestinal macrophages but not to T cells, an effect probably associated with
the high frequency of tolerogenic and Th2-polarized cells in the mucosa of control
individuals or allergic patients.
The role of Gal-3 in allergic inflammation is still controversial. Cortegano and colleagues
showed an anti-allergic effect by using recombinant Gal-3 to suppress IL5 gene transcription
in eosinophils and allergen-specific T cell lines (16). On the contrary, using Gal-3-deficient
(Lgals3−/−) mice, Zuberi et al. assigned a pro-inflammatory role for Gal-3 in a mouse model
of ovalbumin-induced asthma (15). Interestingly, we found that IELs from allergic patients
differentially bind Gal-3, suggesting a potential role of this glycan-binding protein in
modulating T cell homeostasis within the intestinal mucosa in allergy. Further studies are
necessary to understand the effects of Gal-3 on IELs of CMSE patients.
As previously mentioned, other groups have reported that the density of IELs is often
increased in CMSE patients. A differential recognition of these cells by Gal-3 in allergic
patients may represent a compensatory mechanism to restore tolerance and homeostasis.
Gal-3, although mostly described as pro-inflammatory mediator, can also act as an
immunosuppressive agent by inducing T cell apoptosis or negatively regulating T cell
signaling (5, 14). Hence, Gal-3 might exert a biphasic effect acting as a pro-inflammatory
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molecule during the first steps of allergic inflammation in early childhood, while it might
have a regulatory role in limiting allergic processes in early adulthood. These opposite
functions might be exerted through the recognition of differentially-glycosylated membrane
glycoproteins (14). Our findings suggest that the transition from non-allergic to allergic
inflammatory intestinal microenvironment may result in selective glycosylation changes
mainly on the surface of IELs.
In conclusion, our findings provide the first evidence of a selective role of galectin-3
recognition of IELs within the allergic inflammatory mucosa, which may help to unveil the
dominant mechanisms underlying an impaired immune response to food allergens. Future
research is warranted to examine the biological role of galectin-3-glycan lattices within the
normal and inflamed mucosal tissue, and the relevance of these multifunctional proteins in
positively or negatively regulating immunity and/or tolerance within the intestinal
microenvironment.
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Fig. 1. Histopathologic analysis of duodenal samples of allergic and non-allergic patients
Mast cells, eosinophils, IgE+ cells, CD45RO+ cells, CD3+ intraepithelial (IELs) and CD3+
lamina propria (LPLs) cells were counted in 6 villi of duodenal samples of allergic (N: 8)
and non-allergic patients (N: 8). Cells were detected by Giemsa or hematoxylin/eosin
staining (mast cells and eosinophils, respectively) or by immunohistochemistry using anti-
IgE, anti-CD45RO or anti-CD3 monoclonal antibodies. Statistical analysis revealed no
significant differences between different groups of patients. (Original magnification: 1000x
except for CD45RO).
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Fig. 2. Expression of Gal-1 and Gal-3 in duodenal specimens of allergic and non-allergic patients
Gal-1 and Gal-3 expression was assessed by immuno-histochemistry using specific
polyclonal antibodies against Gal-1 and Gal-3 (purified rabbit IgGs) in duodenal samples of
allergic and non-allergic patients. Representative photographs of mucosa from allergic and
non allergic patients were selected to show Gal-1 (A) and Gal-3 (B) positive cells. Control
with serum from non-immunized rabbits is depicted. All samples were analyzed at least
three times in independent experiments (Original magnification: 100x and 400x).
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Fig. 3. SNA binding pattern on duodenal samples: Pattern of α2,6 sialylation in mucosal tissue of
allergic versus non-allergic patients
A) Lectin-histochemistry using biotinylated-SNA and hematoxylin staining was done to
identify SAα2–6-galactose residues. A photograph with stained IEL from an allergic patient
is shown. B) Co-localization studies using a Cy3-conjugated anti-CD3 antibody (red),
biotinylated SNA/ FITC-conjugated streptavidin (green) and DAPI (blue) was performed by
confocal microscopy. C) Lectin binding inhibition assessed by confocal microscopy. Cells
were incubated with biotinylated SNA or biotinylated SNA in the presence of 100 mM
lactose. D) SNA+ cells were quantified by lectin-histochemistry in biopsy specimens of
allergic (N=8) and non-allergic (N=8) patients and no significant difference was found (p=
0.11). E) ST6Gal1 expression was detected using a polyclonal specific antibody by
immunohistochemistry. A control of immunoreactivity is shown using sera from non-
immunized rabbits. All samples were analyzed at least three times in independent
experiments and representative images are shown (Original magnifications: 200x and
1000x).
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Fig. 4. PNA binding pattern in duodenal samples: Detection of asialo core-1-O-glycans in
intestinal glycoproteins of allergic and non-allergic patients
A) Lectin-histochemistry with biotinylated PNA in gut biopsies. B) Co-localization studies
by confocal microscopy using Cy3-conjugated anti-CD3 antibody (red), biotinylated PNA/
FITC-conjugated streptavidin (green) and DAPI (blue nuclear staining); (C) Co-localization
studies by confocal microscopy using biotinylated PNA/ FITC-conjugated streptavidin
(green) and PE-conjugated anti-CD68 antibody (red). D) Lectin binding inhibition studies
assessed by confocal microscopy using biotinylated PNA/ FITC-labeled streptavidin or
biotinylated PNA/ FITC-labeled streptavidin in the presence of 200 mM galactose. E) PNA+
cells were quantified by lectin-histochemistry in biopsy specimens of allergic and non-
allergic patients; no significant differences were found (P:0.14). All samples were analyzed
at least three times in independent experiments and representative images are shown
(Original magnification: 200x).
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Fig. 5. Gal-1-specific ligands on duodenal samples of allergic and non-allergic patients
A) Lectin-histochemistry with biotinylated Gal-1/ HRP-conjugated streptavidin in gut
biopsies. B) Co-localization studies by confocal microscopy using biotinylated Gal-1/ FITC-
conjugated streptavidin (green), Cy3-labeled anti-CD3 or PE-labeled anti-CD138 (red)
antibodies and DAPI (blue nuclear staining). C) Lectin binding inhibition studies assessed
by confocal microscopy with biotinylated Gal-1/ FITC-labeled streptavidin or biotinylated
Gal-1/ FITC-conjugated streptavidin in the presence of 100 mM lactose. D) Gal-1+ cells
were quantified by lectin-histochemistry in biopsy specimens of allergic and non-allergic
patients; no significant differences were found (P= 0.8). All samples were analyzed at least
three times in independent experiments and representative images are shown (Original
magnifications: 200x and 400x).
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Fig. 6. Gal-3-specific ligands in duodenal samples of allergic versus non-allergic patients
A) Lectin-histochemistry with biotinylated Gal-3/ HRP-conjugated streptavidin in gut
biopsies from allergic and non-allergic patients. A control omitting biotinylated Gal-3 is
shown. B) Co-localization studies by confocal microscopy using biotinylated Gal-3/ FITC-
labeled streptavidin (green), Cy3-conjugated anti-CD3 (red) and DAPI (blue nuclear
staining). C) Lectin binding inhibition studies by confocal microscopy with biotinylated
Gal-3/ FITC-labeled streptavidin or biotinylated Gal-3 / FITC-labeled streptavidin in the
presence of 100 mM lactose. D) CD3+ IELs (upper panel; P= 0.9) and Gal-3+ IELs (middle
panel; P<0.0001) were quantified in samples of allergic and non-allergic patients. In the
lower panel the ratio of Gal-3+ IELs/total CD3+IELs is depicted (P<0.001). All samples
were analyzed at least three times in independent experiments and representative images are
shown (Original magnifications: 200x, 400x and 1000x)
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